Source-grounded facts extracted from Vanda Pharmaceuticals Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vanda Pharmaceuticals Inc. shareholders approved Amendment to Company's Amended and Restated 2016 Equity Incentive Plan to increase aggregate number of shares authorized for issuance at the 2026-06-04 meeting.
“The Company’s stockholders approved an amendment to the 2016 Plan to increase the aggregate number of shares authorized for issuance under the 2016 Plan.”
Vanda Pharmaceuticals Inc. shareholders approved Advisory vote on named executive officer compensation at the 2026-06-04 meeting.
“The Company’s stockholders approved on an advisory, non-binding basis the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement.”
Vanda Pharmaceuticals Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“The Company’s stockholders ratified the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Vanda Pharmaceuticals Inc. shareholders approved Election of three directors to serve as Class II directors for a term of three years until the Company's 2029 annual meeting of stockholders at the 2026-06-04 meeting.
“The Company’s stockholders elected the following directors to serve as Class II directors until the Company’s 2029 annual meeting of stockholders.”
Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $51.7 million, net income net loss of $48.6 million (diluted loss per share of $0.82), EPS (diluted loss per share of $0.82). Guidance raised.
“pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9”
Vanda Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $47.5 million, net income $(4.1) million.
“Financial Highlights • Total net product sales from Fanapt ® , HETLIOZ ® and PONVORY ® were $47.5 million in the first quarter of 2024, a 24% decrease compared to $62.5 million in the first quarter of 2023, and a 5% increase compared to $45.3 million in the fourth quarter of 2023. • Fanapt ® net product sales were $20.6 million in the first quarter of 2024, a 10% decrease compared to $22.9 million in the first quarter of 2023, and a 9% decrease compared to $22.6 million in the fourth quarter of 2023. • HETLIOZ ® net product sales were $20.1 million in the first quarter of 2024, a 49% decrease compared to $39.6 million in the first quarter of 2023, and a 5% decrease compared to $21.1 million in the fourth quarter of 2023. The decrease relative to the first quarter of 2023 was the result of continued generic competition in the U.S. • PONVORY ® net product sales were $6.8 million in the first quarter of 2024. The acquisition of PONVORY ® from Actelion Pharmaceuticals Ltd. (Janssen), a Joh”
Vanda Pharmaceuticals Inc. amended Amendment No. 1 with Equiniti Trust Company, LLC (effective 2024-05-03).
“On May 3, 2024, Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into Amendment No. 1 (the “Amendment”) to that certain Rights Agreement, dated as of April 17, 2024 (the “Rights Agreement”), by and between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.”
Vanda Pharmaceuticals Inc. entered into Rights Agreement with Equiniti Trust Company, LLC (effective 2024-04-17).
“The complete terms of the Rights are set forth in a Rights Agreement (the “Rights Agreement”), dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.”
Vanda Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 7, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.